G2Gbio Inc. secured a ₩20 billion (US$13.35 million) investment from Samsung Epis Holdings Co. Ltd. and a joint research and license agreement for two assets, including a long-acting obesity treatment, with subsidiary Samsung Bioepis Co. Ltd. March 16.
Crushing the hopes of drug and device companies, the U.S. Supreme Court’s March 23 orders list showed it denied cert in Takeda Pharmaceutical v. Painters & Allied Trades, which sought to rein in the expansion of class action lawsuits.
Regulatory snapshots for biopharma and med tech, including global submissions and approvals, and other regulatory decisions and designations: Eledon, Intrabio, Novo Nordisk, Rhythm, Siemens.
Biopharma and med-tech happenings, including deals and partnerships, and other news in brief: Caris, Co-Diagnostics, Cosara, Ferring, Hamamatsu, Ibex, Sakura.
Clinical updates for biopharma and med tech, including data readouts and publications: Biodesix, Immunobrain, Innovative Medical, Koite, Pharvaris, Qiagen.
Biopharma and med-tech companies raising money in public or private financings, including: Azitra, Bioxytran, Blue Water Acquisition, Bonus, Capsovision, Earendil, Hansa, Verily.
The first day of Bio-Europe Spring, being held for the first time in Lisbon this year, featured panels on the partnering landscape in specific indications, as well as a more general panel on “Piecing Together the Therapeutic Landscape with Analyst Insights.” One theme of the panel was that by and large, large companies are looking for deals with companies that fit with their existing programs – but that such a fit can come in many forms.
With incidence of kidney cancer rising in the U.K., the National Institute for Health and Care Excellence (NICE) published its first comprehensive guidelines for diagnosing and treating the disease.
Laigo Bio BV has extended its seed round to €17 million (US$19.8 million), after making progress with translating its novel E3 ubiquitin ligase targeted protein degradation technology toward the clinic.
RSS
